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INTRODUCTION
Continuous glucose monitoring (CGM) devices can estimate blood glucose levels with a 1-5min sampling period. However, the relation
between tissue and blood glucose is dynamic and the sensor signal can degrade over time. In addition, CGM readings contains high
frequency noise. However, CGM has the potential to improve performance of glycaemia control and reduce nurse workload. A simple
model was designed and tested to see the effect of inherent CGM error on the insulin therapy protocol, STAR (Stochastic TARgeted).
Modelling Continuous Glucose Monitoring Output
CGM Patients 
Data from 9 patients admitted to the Christchurch Hospital ICU
that were enrolled in an observational pilot study of CGM was
used to generate the CGM error model
Error Model
Using CGM to guide insulin Therapy – Insilco
Virtual Patients 
Virtual trials were performed using retrospective data from 183 
patients treated by accurate glycaemic control protocols at 
Christchurch Hospital ICU between 2011 and 2013.
Results 
- reduced workload by ~50%.
- low level of hypoglycaemia - under the clinically
acceptable value of 5% below <4.0mmol/L
- Shows great promised for the future of CGM and their
use in clinic, newer generation of sensors being
specifically designed for the ICU environment
promising less error and drift
CONCLUSION
The STAR CGM protocol gave good performance and reduced workload by ~50%, reducing the number of measurements per day per patient from 13 to 7. 
The number of hypoglycaemic events increased compared to the current STAR from 0.03% <2.2mmol/L to 0.32%. However, in comparison to other published 
protocols it is still a very low level of hypoglycaemia and less than clinically acceptable value of 5% <4.0mmol/L. More importantly this study shows great 
promise for the future of CGM and their use in clinic. With the a newer generation of sensors, specifically designed for the ICU,  promising less noise and drift 
suggesting that a reduced nurse workload without compromising safety or performance is with in reach.
Number Patients 9
Age (years) 57 [38-64]
Gender (M/F) 5/4
APACHE II score 22 [17 – 28]
Hospital mortality (L/D) (5/4)
Duration of CGM (days) 3.6 [2.5 – 5.7]








































Age (years) 65 [54-72]
Gender (M/F) 123/60
APACHE II score 21 [15 – 25]
Hospital mortality (L/D) 131/52
Whole cohort 
statistics
STAR MC STAR CGM MC Clinical
N 183 183 183
BG 
meas/day/patient
13.5 [12-16] 7.00 [5.9-8.6] 13.0
BG (mmol/L)
6.99 [6.0-8.2] 7.06 [6.0-8.3] 6.80 [5.9- 8.0]
% time in 4.4-8.0 
mmol/L
81.0 72.2 [72-73] 81.3
% time < 4.4 
mmol/L
1.59 4.7 [4.6-4.9] 1.69





TABLE I. SUMMARY OF CGM STUDY PATIENT CHARACTERISTICS. DATA ARE SHOW AS MEDIAN [INTERQUARTILE RANGE] 
WHERE APPROPRIATE
FIGURE I. 1/4 GOLDBERG NOISE
DISTRIBUTION USED TO MODEL THE
HIGH FREQUENCY NOISE SEEN IN CGM 
SIGNALS
FIGURE II. DISTRIBUTION OF ABSOLUTE
DRIFT FOR THE ENTIRE COHORT
FIGURE III. COMPARING CGM TRACES SIMULATED USING THE CGM ERROR MODEL AND BG 
CALIBRATION MEASUREMENTS TO THE REAL CGM TRACE FROM OBSERVATIONAL TRIALS.  
TABLE II. COHORT DEMOGRAPHICS OF THE PATIENTS USED FOR VIRTUAL TRIALS. DATA ARE SHOW AS MEDIAN
[INTERQUARTILE RANGE] WHERE APPROPRIATE
TABLE III. RESULTS OF VIRTUAL TRIAL SIMULATIONS AS WELL AS CLINICAL DATA. DATA ARE PRESENTED AS MEDIAN
[INTERQUARTILE RANGE] WHERE APPROPRIATE. 
